Characteristic Study ID	Intervention(s) and comparator(s)	Randomised / Safety [N]	Deaths [N]	All adverse events [N]	All adverse events [%]	Severe/serious adverse events [N]	Severe/serious adverse events [%]
Kaats 1996	I1: CrP 200 μg/day	33	No participant died	‐	‐	‐	‐
	I2: CrP 400 μg/day	66	No participant died	‐	‐	‐	‐
	C: placebo	55	No participant died	‐	‐	‐	‐
Kaats 1998	I: CrP 400 μg/day	62	No participant died	‐	‐	‐	‐
	C: placebo	60	No participant died	‐	‐	‐	‐
Joseph 1999	I: CrP 1000 μg/day + resistance training	17	No participant died	‐	‐	‐	‐
	C: placebo + resistance training	15	No participant died	‐	‐	‐	‐
Kleefstra 2006	I1: CrP 500 μg/day	17	No participant died	0	0	0	0
	I2: CrP 1000 μg/day	17/15	No participant died	2	13	2	13
	C: placebo	19	No participant died	0	0	0	0
Iqbal 2009	I: CrP 500 μg/day	33	No participant died	‐	‐	‐	‐
	C: placebo	30	No participant died	‐	‐	‐	‐
Volpe 2001	I: CrP 400 μg/day + weight training	22	No participant died	‐	‐	‐	‐
	C: placebo + weight training	20	No participant died	‐	‐	‐	‐
Anton 2008	I: CrP 400 μg/day	21	No participant died	0	0	0	0
	C: placebo	19/18	No participant died	1	6	1	6
Campbell 1999	I: CrP 1000 μg/day + resistance training	9	No participant died	‐	‐	‐	‐
	C: placebo + resistance training	9	No participant died	‐	‐	‐	‐
Yazaki 2010	I: CrP 400 μg/day	40/39	No participant died	1	3	1	3
	C: placebo	40	No participant died	0	0	0	0
Footnotes "‐" denotes not reported C: control; CrP: chromium picolinate; I: intervention